Dave Kelleher, CEO of 4G Clinical, speaks with ACRP about how patient choice will determine the future adoption of decentralized clinical trials.
The clinical trial industry is clearly warming to the ideas behind decentralized clinical trials (DCTs), but it is ultimately patients who will drive the rate of adoption, says Dave Kelleher, CEO of 4G Clinical, a randomization and trial supply management company.
“People like choices, but if patients don’t accept” remote trials, DCTs may not continue to grow in popularity, Kelleher says. In any event, he notes, “Sites are never going away. Clinicians are not going away.”
Amy Ripston, 4G Clinical Vice President of Marketing, has over 20 years of B2B experience, of which she spent 9 years in the bio/pharmaceutical industry. Amy has a knack for identifying market trends, synthesizing content, engaging thought leaders, and connecting businesses with innovative solutions.